Recently the FDA announced a new tablets Manvenclad which may help to treat adult patients with relapsing remitting and active secondary progressive multiple sclerosis.
Multiple Sclerosis is a chronic, inflammatory and autoimmune disease of the central nervous system that may destroy the communication between the brain and other parts of the body. Multiple sclerosis is among the most common causes of neurological disability.
According to the study researchers found that patients who received Manvenclad experienced significantly fewer relapses compared with patients who received Placebo. Manvenclad reduces the progression of disability when compared to Placebo.
- Manvenclad should not be used in pregnant women.
- It should not be used in patients with a current malignancy.
- Other warnings include the risk of decreased lymphocyte counts, infections, bone marrow suppression.
The most common adverse reactions reported by patients receiving Manvenclad in clinical trials include upper respiratory tract infections, headache and decreased lymphocyte counts.